AbbVie, although overvalued, and with little revenue diversification still has the most profitable drug on the US pharmaceutical market, Humira, with a longstanding patent. ABBV still have plenty of momentum to beat it's median price target of $95.
Pfizer looks to have created some distance from its post earnings volatility, established succeeding higher-highs, backed by corporate news of new Operating Chief, and looks like could sustain a positive trend to close out 2017.
